Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial
doi: 10.1016/j.neuropharm.2023.109603 36 ZhangHLiuYChengLMaXLuoX
This article covers the structural pharmacology of both compounds, their distinct mechanisms of action at the receptor level, dosing and stability considerations that affect experimental design, and the specific research contexts where one clearly outperforms the other
About one-third of this group, or 241 people, still had food in their stomachs four hours after eating, meeting the diagnosis criteria for gastroparesis
Given the risk of complications from uncontrolled diabetes, such as the increased risk of wound infections from hyperglycemia, it would be in a patients best interest to continue these medications in the perioperative setting